Patent ID: 11866505
Assignee: PROMETHEUS BIOSCIENCES, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An antibody or antigen binding fragment thereof that binds CD30L, wherein the antibody or antigen binding fragment thereof comprises:
(a) a heavy chain variable region complementarity determining region 1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO: 119; a heavy chain variable region complementarity determining region 2 (CDR-H2) comprising the amino acid sequence set forth in SEQ ID NO: 159; a heavy chain variable region complementarity determining region 3 (CDR-H3) comprising the amino acid sequence set forth in SEQ ID NO: 199; a light chain variable region complementarity determining region 1 (CDR-L1) comprising the amino acid sequence set forth in SEQ ID NO: 319, a light chain variable region complementarity determining region 2 (CDR-L2) comprising the amino acid sequence set forth in SEQ ID NO: 359; and a light chain variable region complementarity determining region 3 (CDR-L3) comprising the amino acid sequence set forth in SEQ ID NO: 399;
(b) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 118; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 158; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 198; a CDR-L1 comprising the amino acid sequence setforthin SEQ IDNO: 318, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 358; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 398.
(c) a CDR-H1 comprising the amino acid sequence setforthin SEQ ID NO: 117; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 157; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 197; a CDR-L1 comprising the amino acid sequence setforthin SEQ ID NO: 317, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 357; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 397;
(d) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 116; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 156; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 196; a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 316, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 356; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 396;
(e) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 115; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 155; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 195; a CDR-L1 comprising the amino acid sequence setforthin SEQ ID NO: 315, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 355; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 395; or
(f) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 629; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 643; a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 657; a CDR-L1 comprising the amino acid sequence setforthin SEQ IDNO: 671, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 685; and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 699.